Stephen Saad, Group Chief Executive, Aspen
The line between research based pharmaceutical companies and generic companies is today less and less relevant, as we have seen in the past few years generic companies climb up the…
Ferring is a speciality, research-driven biopharmaceutical company that identifies, develops, manufactures and markets innovative products in the fields of reproductive health, urology, gastroenterology and endocrinology.
From its origins as a distinctly Scandinavian company, Ferring has developed into a global business with operating units in most important pharmaceutical markets around the world.
Ferring (Pty) Ltd established operations in South Africa in 1996 with a limited portfolio of products. The company has now expanded its activities into a number of other countries within the region including Namibia, Botswana, Kenya and Mauritius. The portfolio of products has grown to include a range of products in the fields of urology, gastroenterology, obstetrics, gynaecology and infertility treatment.
Ferring is committed to a future where it will continue to provide new and innovative medicines by utilising existing and acquired skills and the development of pioneering technologies and, where necessary, through partnerships with academic institutes and other companies.
Ferring’s vision is to be the partner of choice for patients, physicians and business associates offering a leading portfolio of products and services in its key therapeutic areas, using innovative methodologies to provide tailored treatments that function on the body’s own terms.
Contact Details
Route 21 Corporate Park
6 Regency Drive
Irene Ext 30
Gauteng, South Africa
The line between research based pharmaceutical companies and generic companies is today less and less relevant, as we have seen in the past few years generic companies climb up the…
Mr. Godard, you previously worked in Europe for Baxter Edwards Life Sciences, what made you decide to move to South Africa in a smaller company? It is a purely romantic…
Your professional career went back and forth between creating your own business and running a smaller and very dynamic structure and managing over a thousand of employees for multinational organizations.…
You were recently appointed at the head of Eli Lilly South African operations. What is the specific mission you have been given? Eli Lilly South Africa is in an interesting…
Since we interviewed you in 2005, there have been many changes in the market, from consolidation, an increasing generic penetration, to new healthcare reforms… How have you integrated these changes…
An emerging country with a dynamic market, South Africa is widely seen as the gateway to Africa. From major multinational pharmaceutical corporations to burgeoning local generic companies, a wide…
We interviewed Graham Somerville in 2004, the year when IHD, formerly jointly owned by 11 major pharmaceutical companies, was acquired by UTi. We are interviewing you today at the head…
Dr Pillay, South Africa recently became a member of BRICS. With this distinction, we need to improve our healthcare outcomes relative to other BRICS countries. All countries have challenges with…
The South African affiliate was established in June 2003. Could you come back on the main milestones in the company’s development from 2003 onwards? Yamanouchi as an entity was an…
Since we that came to South Africa in 2005 and interviewed you, what have been the main changes both in the market place, and within Sanofi as an organization? The…
In 2005, when Focus Reports interviewed you, you were more towards the start up phase of Pharma Dynamics; and you have significantly grown in the market since then. What new…
Mr. Ehsan, you are the General Manager of IMS Africa since January 2010. What is the strategic importance of South Africa for IMS Global and for your personal country portfolio?…
See our Cookie Privacy Policy Here
